Multi-modality treatment of colorectal liver metastases

被引:42
作者
Cai, Guo-Xiang [1 ,2 ]
Cai, San-Jun [1 ,2 ]
机构
[1] Fudan Univ, Shanghai Canc Ctr, Dept Colorectal Surg, Shanghai 200032, Peoples R China
[2] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai 200032, Peoples R China
关键词
Colorectal cancer; Liver metastases; Multi-modality therapy; RADIOFREQUENCY THERMAL ABLATION; COMPLETE PATHOLOGICAL RESPONSE; CETUXIMAB PLUS IRINOTECAN; LONG-TERM SURVIVAL; HEPATIC RESECTION; NEOADJUVANT CHEMOTHERAPY; SURGICAL RESECTION; 2-STAGE HEPATECTOMY; SCORING SYSTEM; RECTAL-CANCER;
D O I
10.3748/wjg.v18.i1.16
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Liver metastases synchronously or metachronously occur in approximately 50% of colorectal cancer patients. Multimodality comprehensive treatment is the best therapeutic strategy for these patients. However, the optimal pattern of multimodality therapy is still controversial, and it raises several significant concerns. Liver resection is the most important treatment for colorectal liver metastases. The definition of resectability has shifted to focus on the completion of R0 resection and normal liver function maintenance. The role of neoadjuvant and adjuvant chemotherapy still needs to be clarified. The management of either progression or complete remission during neoadjuvant chemotherapy is challenging. The optimal sequencing of surgery and chemotherapy in synchronous colorectal liver metastases patients is still unclear. Conversional chemotherapy, portal vein embolization, two-stage resection, and tumor ablation are effective approaches to improve resectability for initially unresectable patients. Several technical issues and concerns related to these methods need to be further explored. For patients with definitely unresectable liver disease, the necessity of resecting the primary tumor is still debatable, and evaluating and predicting the efficacy of targeted therapy deserve further investigation. This review discusses different patterns and important concerns of multidisciplinary treatment of colorectal liver metastases. (C) 2012 Baishideng. All rights reserved.
引用
收藏
页码:16 / 24
页数:9
相关论文
共 95 条
[1]
Commentary: Radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology [J].
Abdalla, Eddie K. .
AMERICAN JOURNAL OF SURGERY, 2009, 197 (06) :737-739
[2]
Abdalla EK, 2004, ANN SURG, V239, P818, DOI 10.1097/01.sla.0000128305.90650.71
[3]
Portal vein embolization: rationale, technique and future prospects [J].
Abdalla, EK ;
Hicks, ME ;
Vauthey, JN .
BRITISH JOURNAL OF SURGERY, 2001, 88 (02) :165-175
[4]
Radiofrequency ablation permits an effective treatment for colorectal liver metastasis [J].
Abitabile, P. ;
Hartl, U. ;
Lange, J. ;
Maurer, C. A. .
EJSO, 2007, 33 (01) :67-71
[5]
Tumor progression while on chemotherapy - A contraindication to liver resection for multiple colorectal metastases? [J].
Adam, R ;
Pascal, G ;
Castaing, D ;
Azoulay, D ;
Delvart, V ;
Paule, B ;
Levi, F ;
Bismuth, H .
ANNALS OF SURGERY, 2004, 240 (06) :1052-1064
[6]
Adam R, 2001, ANN SURG ONCOL, V8, P347
[7]
Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors [J].
Adam, R ;
Laurent, A ;
Azoulay, D ;
Castaing, D ;
Bismuth, H .
ANNALS OF SURGERY, 2000, 232 (06) :777-784
[8]
Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: Myth or reality? [J].
Adam, Rene ;
Wicherts, Dennis A. ;
de Haas, Robbert J. ;
Aloia, Thomas ;
Levi, Francis ;
Paule, Bernard ;
Guettier, Catherine ;
Kunstlinger, Francis ;
Delvart, Valerie ;
Azoulay, Daniel ;
Castaing, Denis .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1635-1641
[9]
A decision analysis model predicts the optimal treatment pathway for patients with colorectal cancer and resectable synchronous liver metastases [J].
Aloia, Thomas A. ;
Fahy, Bridget N. .
CLINICAL COLORECTAL CANCER, 2008, 7 (03) :197-201
[10]
Altendorf-Hofmann A, 2003, SURG ONCOL CLIN N AM, V12, pxi